Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
Recognized from query: expanded access. Matching terms were moved into the structured fields above when recognized.
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "expanded access" Clear all
Approved For Marketing No phase listed Expanded access

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome
Interventions
3,4-DIAMINOPYRIDINE
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 23, 2026, 5:18 AM EDT
Approved For Marketing No phase listed Expanded access

Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury

NCT02780193
View directory record Official record
Conditions
Cholestasis, Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Up to 18 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jul 23, 2026, 5:18 AM EDT
Approved For Marketing No phase listed Expanded access

Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

NCT02660255
View directory record Official record
Conditions
Epilepsy
Interventions
Cannabidiol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
1 Year to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo

NCT00575549
View directory record Official record
Conditions
Evaluation of Troponin I Levels
Interventions
Dobutamine: Perflutren Lipid Microsphere
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

NCT05095116
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011 3 mg HS
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years and older
U.S. locations
35
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Camarillo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

AZD9291 US Expanded Access Program

NCT02451852
View directory record Official record
Conditions
EGFR T790M Mutation Positive NSCLC
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Anaheim, California • Beverly Hills, California • Burbank, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Naxitamab and GM-CSF in People With Neuroblastoma

NCT04501757
View directory record Official record
Conditions
High-Risk Neuroblastoma
Interventions
Naxitamab/GM-CSF
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jul 23, 2026, 5:18 AM EDT
Available No phase listed Expanded access

Expanded Access of Occlutech's Atrial Flow Regulator

NCT07421557
View directory record Official record
Conditions
Not listed
Interventions
Catheter implantation of Occlutech AFR device
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Maple Grove, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207
View directory record Official record
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access for CC-10004

NCT03740516
View directory record Official record
Conditions
Bechet's Disease
Interventions
CC-10004
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Jul 23, 2026, 5:18 AM EDT
Available No phase listed Expanded access

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer

NCT06836648
View directory record Official record
Conditions
Prostate Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

NCT05002465
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68Ga-PSMA-11, Positron Emission Tomography/Computed Tomography
Drug · Procedure
Lead sponsor
Dana Mathews
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NCT02985658
View directory record Official record
Conditions
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Interventions
Veliparib, Cisplatin, Vinorelbine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 23, 2026, 5:18 AM EDT
Available No phase listed Expanded access

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

NCT03015844
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
131-I-meta-iodobenzylguanidine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
365 Days to 29 Years
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

NCT00701168
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Neoplasm Metastasis
Interventions
yttrium Y 90 microspheres (Therasphere®)
Device
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
19 Years and older
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Canavan-Single Patient IND

NCT05317780
View directory record Official record
Conditions
Canavan Disease
Interventions
rAAV9-CB6-AspA
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Months to 24 Months · Male only
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jul 23, 2026, 5:18 AM EDT
Available No phase listed Expanded access

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

NCT05572970
View directory record Official record
Conditions
Cancer
Interventions
Balstilimab, Zalifrelimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access

NCT01797276
View directory record Official record
Conditions
Mitochondrial Enzyme Deficiencies
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jul 23, 2026, 5:18 AM EDT
Approved For Marketing No phase listed Expanded access

Himalaya Early Access Program

NCT05345678
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Newark, Delaware • Minneapolis, Minnesota • Reno, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 23, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.

NCT04772378
View directory record Official record
Conditions
Parkinson Disease
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
76 Years to 95 Years
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 23, 2026, 5:18 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768
View directory record Official record
Conditions
Total Parenteral Nutrition-Induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 23, 2026, 5:18 AM EDT